Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of HTL18318 in healthy young and elderly adults
NL-OMON46086Active, not recruiting
- Sponsor
- Heptares Therapeutics
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing HTL18318 multiple ascending dose with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, Vital sign abnormalities and 13 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON46086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46086.